Our grit drives solutions for patients. Every day, we strive to advance our pipeline of innovative medicines to treat rare diseases. By targeting the CXCR4 pathway, our novel medicines are designed to restore healthy immunity in patients with rare diseases.
Aberrant functioning of CXCR4 is associated with certain PI diseases. X4 has initiated a phase 3 clinical trial for lead candidate, Mavorixafor, for the PI disease, WHIM Syndrome.
X4 is developing novel, oral medicines designed to treat a range of rare diseases, including primary immunodeficiency diseases and rare cancers, such as lymphomas.
August 06, 2019
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq...
X4 Pharmaceuticals does not review or control the content on the website to which this hyperlink connects and this hyperlink does not constitute an endorsement by X4 Pharmaceuticals of the content of any non-X4 Pharmaceuticals website.